hCG Results: What Studies Measured and When
What published studies measured for hCG, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Testosterone response | Urinary and recombinant hCG gave similar testosterone peaks and timing, apart from a mildly lower early (<48 h) response with urinary. | Human RCT | Clinical endocrinology 2024, PMID 38446525 |
| Spermatogenesis | 23 of 30 subjects achieved spermatogenesis, median time 12 months. | Human RCTn = 30 | Endocrine practice 2024, PMID 39025301 |
| Sperm production with hCG/hMG | Sperm produced in 26/103 (25.24%) on hCG/hMG versus 62/117 (52.99%) on GnRH pulse therapy. | Human RCTn = 220 | Medicine 2019, PMID 31374027 |
| Testosterone | Testosterone rose in all groups to a final mean of 5.17 nmol/L (223% increase) with no difference between hCG, clomiphene or both. | Human RCTn = 282 | BJU international 2018, PMID 29772111 |
| Sperm concentration >= 1.0 x 10(6)/mL | 51.5% (17/33) continual and 55.9% (19/34) sequential FSH/hCG reached sperm concentration of at least 1.0 x 10(6)/mL. | Human RCTn = 67 | The Journal of clinical endocrinology and metabolism 2015, PMID 25825944 |
| Serum testosterone after a single dose | Both recombinant hCG doses raised serum and urine testosterone and suppressed LH in healthy men. | Human RCT | Clinical endocrinology 2009, PMID 19170708 |
| Lean body mass and fat mass | Lean body mass rose by about 2 kg (P < 0.001), body weight about 1 kg and fat mass fell about 1 kg (P < 0.05). | Human RCTn = 40 | The Journal of clinical endocrinology and metabolism 2002, PMID 12107212 |
| Muscle strength and function | Muscle strength was not significantly increased. | Human RCTn = 40 | The Journal of clinical endocrinology and metabolism 2002, PMID 12107212 |
| Testis volume | Testis volume fell by about 5 ml (P < 0.05). | Human RCTn = 40 | The Journal of clinical endocrinology and metabolism 2002, PMID 12107212 |
| Weight loss vs placebo | hCG showed no advantage over placebo for any recorded variable in obese women on a diet. | Human RCTn = 40 | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1990, PMID 2405506 |
| Weight loss vs placebo | No significant difference in weight loss, waist/hip circumference or hunger between hCG and placebo. | Human RCTn = 51 | The American journal of clinical nutrition 1976, PMID 786001 |
| Body composition | hCG treatment lowered insulin resistance, triglycerides, body fat ratio and waist-to-hip ratio and raised fat free mass in IHH. | Human uncontrolled trialn = 16 | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2016, PMID 26485362 |
| Spermatogenesis and pregnancy | Gonadotropin therapy induced spermatogenesis in 74% (mean 11.8 months) and pregnancy in 52% of couples with a child wish. | Meta-analysisn = 1583 | Andrology 2026, PMID 41987691 |
| Dual vs hCG alone | Combined gonadotropin therapy beat hCG monotherapy. | Meta-analysisn = 1583 | Andrology 2026, PMID 41987691 |
| Spermatogenesis hCG alone vs hCG + FSH | Spermatogenesis 86% with hCG + FSH versus 40% with hCG alone. | Meta-analysisn = 5328 | European journal of endocrinology 2024, PMID 38128110 |
| Spermatogenesis success rate | Gonadotropin therapy achieved spermatogenesis in 75% (69-81) of men with HH. | Meta-analysis | Andrology 2014, PMID 25271205 |
| Management of steroid-induced hypogonadism | The review lists hCG among management strategies for anabolic steroid-associated hypogonadism; no quality trials met inclusion. | Review | Fertility and sterility 2014, PMID 24636400 |
| Efficacy in obesity | Meta-analysis found no scientific evidence that hCG is effective for obesity. | Meta-analysis | British journal of clinical pharmacology 1995, PMID 8527285 |
- Approved product: urinary hCG (Novarel, Pregnyl) is FDA-approved for prepubertal cryptorchidism, selected cases of hypogonadotropic hypogonadism in males, and ovulation induction in women. Both labels state hCG has not been demonstrated to be effective adjunctive therapy for obesity.
- The IVF trigger indication in the labels is not summarised here.
- Weight-loss evidence is negative: two double-blind RCTs, a meta-analysis and the label all find no benefit over diet alone.
- No hCG study was found for hair growth, menopause, erectile dysfunction or sex drive.
- Muscle-growth evidence: one placebo-controlled RCT in older men (12107212) found lean mass +~2 kg but no strength change; one pre/post study in IHH (26485362). No trial in healthy athletes or bodybuilders was found; bodybuilding relevance is limited to an anti-doping hormone study (19170708) and a review of steroid-induced hypogonadism (24636400).
- Most trials are in men with hypogonadotropic hypogonadism for fertility; dose regimens (e.g., 2000 U three times weekly) are not generic recommendations.
- The labels contain no numeric half-life; the 5.8-day figure is from a study in gonadotrophin-deficient men and covers both urinary and recombinant hCG.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| <48 h | Early testosterone response after single dose | Human RCT | Clinical endocrinology 2024, PMID 38446525 |
| 1 and 3 months | Morning total testosterone sampling | Human RCTn = 282 | BJU international 2018, PMID 29772111 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does hCG take to work?
The studies we summarise measured outcomes at set points, for example Early testosterone response after single dose at <48 h; Morning total testosterone sampling at 1 and 3 months. Timelines outside studies vary.
Do you show hCG before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on hCG
DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.Half-lifeWhat is measured, by route, and what is not.
Sources
- 1Single and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men.Clinical endocrinology · 2024PMID 38446525Accessed 2 Oct 2026
- 2Effect of Combined Low Dose Human Gonadotropic Hormone, Follicle Stimulating Hormone, and Testosterone Therapy (LFT Regimen) Versus Conventional High Dose Human Gonadotropic Hormone and Follicle Stimulating Hormone on Spermatogenesis and Biomarkers in Men With Hypogonadotropic Hypogonadism.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024PMID 39025301Accessed 2 Oct 2026
- 3Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism.Medicine · 2019PMID 31374027Accessed 2 Oct 2026
- 4Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study.BJU international · 2018PMID 29772111Accessed 2 Oct 2026
- 5Sequential Versus Continual Purified Urinary FSH/hCG in Men With Idiopathic Hypogonadotropic Hypogonadism.The Journal of clinical endocrinology and metabolism · 2015PMID 25825944Accessed 2 Oct 2026
- 6Effects of recombinant human LH and hCG on serum and urine LH and androgens in men.Clinical endocrinology · 2009PMID 19170708Accessed 2 Oct 2026
- 7A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.The Journal of clinical endocrinology and metabolism · 2002PMID 12107212Accessed 2 Oct 2026
- 8Human chorionic gonadotrophin and weight loss. A double-blind, placebo-controlled trial.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde · 1990PMID 2405506Accessed 2 Oct 2026
- 9Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study.The American journal of clinical nutrition · 1976PMID 786001Accessed 2 Oct 2026
- 10The Effects of Gonadotropin Replacement Therapy on Metabolic Parameters and Body Composition in Men with Idiopathic Hypogonadotropic Hypogonadism.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2016PMID 26485362Accessed 2 Oct 2026
- 11Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism-A Systematic Review and Meta-Analysis.Andrology · 2026PMID 41987691Accessed 2 Oct 2026
- 12Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.European journal of endocrinology · 2024PMID 38128110Accessed 2 Oct 2026
- 13Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study.Andrology · 2014PMID 25271205Accessed 2 Oct 2026
- 14Anabolic steroid-induced hypogonadism: diagnosis and treatment.Fertility and sterility · 2014PMID 24636400Accessed 2 Oct 2026
- 15The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis.British journal of clinical pharmacology · 1995PMID 8527285Accessed 2 Oct 2026
Found an error? Report a correction.